// App-Quantinova.ai

7053 : Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.

Researchers

Presenter

  • Utz Krug

Principal Investigators

  • Nicola Knoblauch

  • Carsten Mller-Tidow

  • Wolfgang E. Berdel

  • Joachim Gerss

  • Christoph Schliem

  • Ann Stefanie Wiebe

Medical Centers

  • University Hospital of Muenster, Muenster, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • Circulating tumor cells

Drug/Treatment

  • Cytarabine liposomal

  • Nintedanib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01488344

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved